{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T02:10:40Z","timestamp":1784167840708,"version":"3.55.0"},"reference-count":13,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2016,5,24]],"date-time":"2016-05-24T00:00:00Z","timestamp":1464048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2016,5,24]],"date-time":"2016-05-24T00:00:00Z","timestamp":1464048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy"],"published-print":{"date-parts":[[2017]]},"abstract":"<b><i>Background:<\/i><\/b> European centers (n = 226) involved in the Tigecycline Evaluation and Surveillance Trial (TEST, 2004-2014) submitted data and bacterial isolates. <b><i>Methods:<\/i><\/b> Minimal inhibitory concentrations and susceptibility were determined using Clinical and Laboratory Standards Institute methods and European Committee on Antimicrobial Susceptibility Testing breakpoints. <b><i>Results:<\/i><\/b> The rates of the following resistant pathogens increased from 2004 to 2014: extended-spectrum \u03b2-lactamase (ESBL)-positive <i>Escherichia coli<\/i> (from 8.9 to 16.9%), multidrug-resistant <i>Acinetobacter baumannii<\/i> complex (from 15.4 to 48.5%), and ESBL-positive <i>Klebsiella pneumoniae<\/i> (from 17.2 to 23.7%). The rate of methicillin-resistant <i>Staphylococcus aureus<\/i> was 27.5% in 2004 and 28.9% in 2014. Resistance to the carbapenems (imipenem and meropenem) was 37.4 and 14.5% for <i>A. baumannii<\/i> complex and <i>Pseudomonas aeruginosa<\/i>, respectively. Carbapenem resistance was \u22644.3% among the Enterobacteriaceae and 0.2% against <i>Streptococcus pneumoniae.<\/i> The resistance to tigecycline ranged between 7.4% against ESBL-producing <i>K. pneumoniae <\/i>and 0.0% against <i>S. aureus.<\/i><b><i>Conclusions:<\/i><\/b> The carbapenems and tigecycline were active against Enterobacteriaceae. Agents with activity against <i>A. baumannii<\/i> complex and <i>P. aeruginosa<\/i> are limited. The carbapenems, tigecycline, linezolid, and vancomycin were active against Gram-positive organisms.<\/jats:p>","DOI":"10.1159\/000445022","type":"journal-article","created":{"date-parts":[[2016,5,23]],"date-time":"2016-05-23T21:38:48Z","timestamp":1464039528000},"page":"1-11","source":"Crossref","is-referenced-by-count":26,"title":["Antimicrobial Susceptibility among European Gram-Negative and Gram-Positive Isolates Collected as Part of the Tigecycline Evaluation and Surveillance Trial (2004-2014)"],"prefix":"10.1159","volume":"62","author":[{"given":"Arne C.","family":"Rodloff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Dowzicky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2016,5,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2011.02.003"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2014.05.001"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.02.003"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.10.008"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1159\/000376569"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/2047-2994-2-6"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05100-14"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159\/000375440"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.06.044"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00058-14"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-009-9225-x"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks429"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3410\/f.717953814.793459435"}],"container-title":["Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/445022","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/445022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T17:52:55Z","timestamp":1745430775000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000445022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,24]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,14]]}},"URL":"https:\/\/doi.org\/10.1159\/000445022","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.5129665","asserted-by":"subject"}]},"ISSN":["0009-3157","1421-9794"],"issn-type":[{"value":"0009-3157","type":"print"},{"value":"1421-9794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,24]]}}}